INR 698.8
(3.55%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 1.19 Billion INR | 32.56% |
2022 | 898.57 Million INR | -40.81% |
2021 | 1.51 Billion INR | 22.83% |
2020 | 1.23 Billion INR | 68.38% |
2019 | 734.03 Million INR | 86.19% |
2018 | 394.24 Million INR | 351.7% |
2017 | 87.28 Million INR | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | 461.49 Million INR | 3.37% |
2024 Q1 | 446.44 Million INR | 20.88% |
2023 Q1 | 285.11 Million INR | -25.42% |
2023 Q4 | 369.32 Million INR | 23.99% |
2023 Q3 | 297.87 Million INR | 24.72% |
2023 Q2 | 238.84 Million INR | -16.23% |
2023 FY | 1.19 Billion INR | 32.56% |
2022 Q4 | 382.29 Million INR | 301.95% |
2022 Q3 | 95.11 Million INR | -43.6% |
2022 Q2 | 168.62 Million INR | -33.22% |
2022 Q1 | 252.49 Million INR | -45.36% |
2022 FY | 898.57 Million INR | -40.81% |
2021 Q2 | 582.2 Million INR | 652.29% |
2021 FY | 1.51 Billion INR | 22.83% |
2021 Q1 | 77.39 Million INR | -84.12% |
2021 Q4 | 462.11 Million INR | 16.58% |
2021 Q3 | 396.4 Million INR | -31.91% |
2020 Q3 | 156.93 Million INR | 0.0% |
2020 FY | 1.23 Billion INR | 68.38% |
2020 Q4 | 487.42 Million INR | 210.6% |
2019 FY | 734.03 Million INR | 86.19% |
2018 FY | 394.24 Million INR | 351.7% |
2017 FY | 87.28 Million INR | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Biocon Limited | 10.22 Billion INR | 88.351% |
Blue Jet Healthcare Limited | 1.63 Billion INR | 27.259% |
Concord Biotech Limited | 3.08 Billion INR | 61.34% |
Dishman Carbogen Amcis Limited | -1.53 Billion INR | 177.624% |
Jubilant Ingrevia Limited | 1.82 Billion INR | 34.871% |
Lyka Labs Limited | -24.89 Million INR | 4884.848% |
Panacea Biotec Limited | -11.73 Million INR | 10254.646% |
Piramal Pharma Limited | 178.2 Million INR | -568.429% |
SMS Lifesciences India Limited | 90.92 Million INR | -1209.982% |
Syngene International Limited | 5.1 Billion INR | 76.644% |
TAKE Solutions Limited | -1.19 Billion INR | 199.577% |
Zota Health Care Limited | -143.47 Million INR | 930.184% |